AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Abbott Laboratories reported a trading volume of $784 million on April 21, 2025, marking a 42.92% decrease from the previous day. The company's trading volume ranked 90th among all stocks traded that day. The stock price of
(ABT) decreased by 0.83%.Abbott Laboratories has announced that it will be hosting a conference call to discuss its first-quarter 2025 financial results. The call is scheduled for April 23, 2025, at 8:30 AM Eastern Time. Investors and analysts are encouraged to participate in the call to gain insights into the company's performance and future outlook.
Abbott Laboratories has received approval from the U.S. Food and Drug Administration (FDA) for its new FreeStyle Libre 3 system. This system is designed to provide continuous glucose monitoring for people with diabetes, offering improved accuracy and convenience compared to previous models. The approval is expected to boost the company's diabetes care segment, which is a key growth driver for Abbott.
Abbott Laboratories has also announced that it will be expanding its manufacturing capabilities in Ireland. The company plans to invest $1 billion in a new state-of-the-art facility that will produce a range of medical devices and diagnostics. This expansion is part of Abbott's broader strategy to increase its global manufacturing footprint and improve supply chain resilience.
Market Watch column provides a thorough analysis of stock market fluctuations and expert ratings.

Dec.19 2025

Dec.19 2025

Dec.19 2025

Dec.18 2025

Dec.18 2025
Daily stocks & crypto headlines, free to your inbox
Comments
No comments yet